한국임상수의학회지 (Journal of Veterinary Clinics)

  • 제34권6호
  • /
  • Pages.441-444
  • /
  • 2017
  • /
  • 1598-298X(pISSN)
  • /
  • 2384-0749(eISSN)
한국임상수의학회 (The Korean Society of Veterinary Clinics)
권호 표지
DOI QR코드

DOI QR Code

Metronomic Chemotherapy with Toceranib Phosphate for a Disseminated Histiocytic Sarcoma in a Miniature Schnauzer Dog

  • Hong, Hwaran (College of Veterinary Medicine, Chungnam National University) ;
  • Lim, Seula (College of Veterinary Medicine, Chungnam National University) ;
  • Shin, Hye-Ri (College of Veterinary Medicine, Chungnam National University) ;
  • Choi, Ho-jung (College of Veterinary Medicine, Chungnam National University) ;
  • Lee, Haebum (College of Veterinary Medicine, Chungnam National University) ;
  • Song, Kun-Ho (College of Veterinary Medicine, Chungnam National University) ;
  • Seo, Kyoung-Won (College of Veterinary Medicine, Chungnam National University)
  • 투고 : 2017.08.29
  • 심사 : 2017.10.11
  • 발행 : 2017.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

A 15-year-old spayed female Miniature Schnauzer was presented for unilateral foreleg lameness and pain. On physical examination, left elbow joint swelling and stiffness were identified. On a computed tomography (CT) scan, a periosteal reaction of the left humerus from the distal metaphysis to the epiphysis and cortical destruction of the medial condyle was observed. Based on blood tests, histopathology, and immunohistochemistry, it was concluded as a skeletal histiocytic sarcoma. Since the patient's pain was not controlled despite application of a fentanyl patch, a left forelimb amputation was decided upon as part of the palliative therapy. Metronomic chemotherapy with toceranib phosphate and pamidronate was initiated. Toceranib was administered for 3 months without the development of any adverse effects except mild neutropenia. However, 3 months after initiating treatment, the toceranib was discontinued due to moderate gastrointestinal disturbances. Over the next 2 months, a left mandibular bone mass and cortical bone destruction in the bilateral tibia and tarsal joint were identified on CT. The patient became unwilling to eat and was noted to have severe skeletal pain. The anorexia and lethargy were progressively worsening and the owner decided to euthanize the patient. A necropsy was performed and the patient was definitively diagnosed with disseminated histiocytic sarcoma based on histopathologic and immunohistochemical analyses. This report describes a Miniature Schnauzer dog with DHS managed with surgical removal and metronomic chemotherapy with toceranib that survived with an improved quality of life for 7 months.

키워드

참고문헌

  1. Abadie J, Hedan B, Cadieu E, De Brito C, Devauchelle P, Bourgain C, Parker HG, Vaysse A, Margaritte-Jeannin P, Galibert F, Ostrander EA, Andre C. Epidemiology, pathology, and genetics of histiocytic sarcoma in the Bernese mountain dog breed. J Hered 2009; 100: 19-27. https://doi.org/10.1093/jhered/esp039
  2. Affolter VK, Moore PF. Localized and disseminated histiocytic sarcoma of dendritic cell origin in dogs. Vet Pathol 2002; 39: 74-83. https://doi.org/10.1354/vp.39-1-74
  3. Bernabe LF, Portela R, Nguyen S, Kisseberth WC, Pennell M, Yancey MF, London CA. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose. BMC Vet Res 2013; 9: 190. https://doi.org/10.1186/1746-6148-9-190
  4. Cannon C, Borgatti A, Henson M, Husbands B. Evaluation of a combination chemotherapy protocol including lomustine and doxorubicin in canine histiocytic sarcoma. J Small Anim Pract 2015; 56: 425-429. https://doi.org/10.1111/jsap.12354
  5. Dervisis NG, Kiupel M, Qin Q, Cesario L. Clinical prognostic factors in canine histiocytic sarcoma. Vet Comp Oncol 2017; 15: 1171-1180. https://doi.org/10.1111/vco.12252
  6. Friedrichs KR, Thomas C, Plier M, Andrews GA, Chavey PS, Young KM. Evaluation of serum ferritin as a tumor marker for canine histiocytic sarcoma. J Vet Intern Med 2010; 24: 904-911. https://doi.org/10.1111/j.1939-1676.2010.0543.x
  7. Hayden DW, Waters DJ, Burke BA, Manivel JC. Disseminated Malignant Histiocytosis in a Golden Retriever: Clinicopathologic, Ultrastructural, and Immunohistochemical Findings. Vet Pathol 1993; 31: 256-64.
  8. Lenz JA, Furrow E, Craig LE, Cannon CM. histiocytic sarcoma in 14 miniature schnauzers- a new breed presdisposition? J Small Anim Pract 2017; 58: 461-467. https://doi.org/10.1111/jsap.12688
  9. Liptak JM, Dernell WS, Straw RC, Rizzo SA, Lafferty MH, Withrow SJ. Proximal radial and distal humeral osteosarcoma in 12 dogs. J Am Anim Hosp Assoc 2004; 40: 461-467. https://doi.org/10.5326/0400461
  10. London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, Henry CJ, Mitchener KL, Klein MK, Hintermeister JG, Bergman PJ, Couto GC, Mauldin GN, Michels GM. Multi-center, placebo-controlled, doubleblind, randomized study of oral toceranib phosphate (SU- 11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res 2009; 15: 3856-3865. https://doi.org/10.1158/1078-0432.CCR-08-1860
  11. London C, Mathie T, Stingle N, Clifford C, Haney S, Klein MK, Beaver L, Vickery K, Vail DM, Hershey B, Ettinger S, Vaughan A, Alvarez F, Hillman L, Kiselow M, Thamm D, Higginbotham ML, Gauthier M, Krick E, Phillips B, Ladue T, Jones P, Bryan J, Gill V, Novasad A, Fulton L, Carreras J, McNeill C, Henry C, Gillings S. Preliminary evidence for biologic activity of toceranib phosphate (Palladia(R)) in solid tumours. Vet Comp Oncol 2012; 10: 194-205. https://doi.org/10.1111/j.1476-5829.2011.00275.x
  12. Plumb. D.C. Toceranib Phosphate. In: Plumb's Veterinary Drug Handbook, 8th ed. St. Paul: Wiley Blackwell. 2015: 1419-1422.
  13. Schlick K, Aigelsreiter A, Pichler M, Reitter S, Neumeister P, Hoefler G, Beham-Schmid C, Linkesch W. Histiocytic sarcoma- targeted therapy: novel therapeutic options? A series of 4 cases. Onkologie 2012; 35: 447-450. https://doi.org/10.1159/000340066
  14. Schultz RM, Puchalski SM, Kent M, Moore PF. Skeletal lesions of histiocytic sarcoma in nineteen dogs. Vet Radiol Ultrasound 2007; 48: 539-543. https://doi.org/10.1111/j.1740-8261.2007.00292.x
  15. Treggiari E, Ressel L, Polton GA, Benoit J, Desmas I, Blackwood L. Clinical outcome, PDGFR${\beta}$ and KIT expression in feline histiocytic disorders: a multicentre study. Vet Comp Oncol 2017; 15: 65-77. https://doi.org/10.1111/vco.12142
  16. Ehrhart NP, Ryan SD, Fan TM. Tumors of the skeletal system. In: Withrow & MacEwn's Small Animal Clinical Oncology, 5th ed. St. Louis: Saunders Elsevier. 2013: 463-495.
  17. Wouda RM, Miller ME, Chon E, Stein TJ. Clinical effects of vinorelbine administration in the management of various malignant tumor types in dogs: 58 cases (1997-2012). J Am Vet Med Assoc 2015; 246: 1230-1237. https://doi.org/10.2460/javma.246.11.1230
  18. Zavodovskaya R, Liao AT, Jones CL, Yip B, Chien MB, Moore PF, Cheryl A. Evaluation of dysregulation of the receptor tyrosine kinases Kit, Flt3, and Met in histiocytic sarcomas of dogs. Am J Vet Res 2006; 67: 633-641. https://doi.org/10.2460/ajvr.67.4.633

피인용 문헌

  1. Retrospective evaluation of toceranib phosphate (Palladia) for treatment of different tumor types in 31 dogs vol.61, pp.1, 2021, https://doi.org/10.14405/kjvr.2021.61.e10